Zoulika Kherrouche

Lille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.

Journal: Nature communications

Published: August 09, 2023

Combined regulation of pro-inflammatory cytokines production by STAT3 and STAT5 in a model of B. pertussis infection of alveolar macrophages.

Combined regulation of pro-inflammatory cytokines production by STAT3 and STAT5 in a model of B. pertussis infection of alveolar macrophages.

Journal: Frontiers in immunology

Published: July 06, 2023

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

Journal: FEBS letters

Published: January 19, 2023

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

Journal: Molecular oncology

Published: June 22, 2022

When the MET receptor kicks in to resist targeted therapies.

When the MET receptor kicks in to resist targeted therapies.

Journal: Oncogene

Published: February 15, 2021

Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.

Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 29, 2019

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 09, 2019

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.

Journal: Clinical lung cancer

Published: September 05, 2018

MET amplification increases the metastatic spread of EGFR-mutated NSCLC.

MET amplification increases the metastatic spread of EGFR-mutated NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 19, 2018

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 18, 2018

The multiple paths towards MET receptor addiction in cancer.

The multiple paths towards MET receptor addiction in cancer.

Journal: Oncogene

Published: December 04, 2017

MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer

MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer

Journal: Revue des maladies respiratoires

Published: September 02, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026